

## DAFTAR PUSTAKA

- Aisyah, N., Andayani, T. M., Pusparani, D. A., Farmasi, A., Banjarmasin, I., Farmasi, F., Gadjah Mada, U., Kedokteran, K., Masyarakat, D., Keperawatan, U., & Gadjah, M. (2018). ANALISIS BIAYA KEMOTERAPI PADA PASIEN RAWAT INAP KANKER PAYUDARA PESERTA JKN DI RSUD ULIN BANJARMASIN. In *Jurnal Ilmiah Ibnu Sina* (Vol. 3, Issue 2).
- Astuti, N. P., & Nuraini, N. (2018). *Analisis biaya pengobatan pasien kanker payudara di rumah sakit rujukan nasional*. *Jurnal Kesmas: Jurnal Kesehatan Masyarakat Nasional*, **13**(1), 47–53. <https://doi.org/10.21109/kesmas.v13i1.1978>
- BPJS Kesehatan. (2021). *Panduan Praktis Pelayanan Kanker Payudara dalam Program JKN*. Jakarta: BPJS Kesehatan.
- Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clinical Cancer Research*, *14*(5), 1368–1376. <https://doi.org/10.1158/1078-0432.CCR-07-1658>
- Dewantari, S., 2012, Evaluasi penggunaan obat analgetic pada pasien kanker payudara di Rumah sakit umum daerah DR. Moewardi tahun 2010.[skripsi], Surakarta, Fakultas Farmasi Universitas Muhammadiyah Surakarta.
- Eroles, P.; Bosch, A.; Pérez-Fidalgo, J.A.; Lluch, A. *Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways*. *Cancer Treat. Rev.* 2012, *38*, 698–707.
- Friedman, G. D., Oestreicher, N., Chan, J., Quesenberry, C. P., Udaltsova, N., & Habel, L. A. (2006). Antibiotics and risk of breast cancer: Up to 9 years of follow-up of 2.1 million women. *Cancer Epidemiology*

*Biomarkers and Prevention*, 15(11), 2102–2106.  
<https://doi.org/10.1158/1055-9965.EPI-06-0401>

Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., Backlund, M. G., Yin, Y., Khramtsov, A. I., Bastein, R., Quackenbush, J., Glazer, R. I., Brown, P. H., Green, J. E., Kopelovich, L., ... Perou, C. M. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biology*, 8(5).  
<https://doi.org/10.1186/gb-2007-8-5-r76>

Hopper, J. L., Dite, G. S., MacInnis, R. J., Liao, Y., Zeinomar, N., Knight, J. A., Southey, M. C., Milne, R. L., Chung, W. K., Giles, G. G., Genkinger, J. M., McLachlan, S. A., Friedlander, M. L., Antoniou, A. C., Weideman, P. C., Glendon, G., Nesci, S., Andrulis, I. L., Buys, S. S., ... Terry, M. B. (2018). Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC). *Breast Cancer Research*, 20(1). <https://doi.org/10.1186/s13058-018-1056-1>

Hu, X., Zhang, Q., Xing, W., & Wang, W. (2022). Role of microRNA/lncRNA Intertwined With the Wnt/ $\beta$ -Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer. In *Frontiers in Pharmacology* (Vol. 13). Frontiers Media S.A.  
<https://doi.org/10.3389/fphar.2022.814971>

Kemenkes RI. 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Indonesia.

Kementerian Kesehatan Republik Indonesia. (2016). *Profil Kesehatan Indonesia Tahun 2015*. Jakarta: Kementerian Kesehatan RI.

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—

- An updated review. In *Cancers* (Vol. 13, Issue 17). MDPI. <https://doi.org/10.3390/cancers13174287>
- National Comprehensive Cancer Network. (2023). *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 4.2023.*
- Musnelina, L., Pontoan, J., & Martin, C. J. (2019). *ANALISIS EFEKTIVITAS BIAYA KEMOTERAPI PADA PASIEN KANKER PAYUDARA DI RSPAD GATOT SOEBROTO JAKARTA* (Vol. 5, Issue 1).
- Nailis Sa'adah, N., Puji, A., Nurhayati, D., & Shovitri, M. (2016). The Anticancer Activity of the Marine Sponge *Aaptos suberitoides* to Protein Profile of Fibrosarcoma Mice (*Mus musculus*). In *The Journal for Technology and Science* (Vol. 27, Issue 3).
- Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016). Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. In *npj Breast Cancer* (Vol. 2, Issue 1). Nature Publishing Group. <https://doi.org/10.1038/npjbcancer.2016.36>
- Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016). Features of triple-negative breast cancer Analysis of 38,813 cases from the national cancer database. *Medicine (United States)*, 95(35). <https://doi.org/10.1097/MD.0000000000004614>
- Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*, 24, S26–S35. <https://doi.org/10.1016/j.breast.2015.07.008>
- Putri, S. R., Wibowo, R. A., & Prasetyo, B. (2019). *Analisis Penggunaan Kemoterapi pada Pasien Kanker Payudara di RSUP Dr. Sardjito.* *Jurnal Kefarmasian Indonesia*, 9(1), 24–30

- Santoso, A., Sulistyanningrum, I. H., Rosyid, A., Cahyono, E. B., Wirastuti, K., & Riyanto, B. (2020). Jurnal Farmasi Sains dan Praktis PERBANDINGAN BIAYA RIIL DENGAN TARIF INA-CBG'S PENYAKIT KANKER PAYUDARA PADA ERA JAMINAN KESEHATAN NASIONAL COMPARATIVE OF REAL COST AGAINST THE PRICE OF INA-CBG'S BREAST CANCER AND ITS AFFECTING FACTORS IN JKN PROGRAM ERA. In *JFSP* (Vol. 6, Issue 1). <http://journal.ummgl.ac.id/index.php/pharmacy>
- Sitorus, R., Handayani, D., & Lubis, E. Y. (2020). *Faktor-faktor yang berhubungan dengan keterlambatan diagnosis kanker payudara di Indonesia*. *Jurnal Kesehatan Masyarakat Andalas*, **15**(2), 85–92.
- Saputra Liambo, I., Frisithody, A., Hajrul Malaka, M., Farmasi Rumah Sakit Jiwa Provinsi Sulawesi Tenggara, I., Sutomo No, J., Farmasi Universitas Halu Oleo, F., & Hijau Bumi Tridharma Anduonohu JI E A Mokodompit Kendari, K. H. (2022). Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara Review: Pathophysiology, Epidemiology, and Cell Line of Breast Cancer. *Pharmauho: Jurnal Farmasi*, **8**(1). <https://doi.org/10.33772/pharmauho.v8i>
- Slamet, R. Y., Hapsari, D., & Wahyudi, A. (2021). *Efektivitas dan Efisiensi Penggunaan Paclitaxel dalam Kemoterapi Kanker Payudara*. *Jurnal Farmasi Klinik Indonesia*, **10**(2), 75–81.
- Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. (2017). Risk factors and preventions of breast cancer. In *International Journal of Biological Sciences* (Vol. 13, Issue 11, pp. 1387–1397). Ivyspring International Publisher. <https://doi.org/10.7150/ijbs.21635>
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). *Pharmacotherapy Handbook: Ninth Edition*.

Yosmar, R., Ningsih, L., & Ifmaily. (2020). Studi Analisa Efektivitas Biaya pada Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP DR. M. Djamil Padang. *Jurnal Farmasi Higea*, 12(1), 19–31.

